142 related articles for article (PubMed ID: 38561582)
1. Osteoporotic quality of life, self-efficacy, and fracture protection behaviors in postmenopausal women.
Ünver G; Özlü A; Erdoğan A; Özdemir MF; Üstündağ S
Arch Osteoporos; 2024 Apr; 19(1):22. PubMed ID: 38561582
[TBL] [Abstract][Full Text] [Related]
2. Asia-pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures.
Huang CF; Chen JF; Reid IR; Chan WP; Ebeling PR; Langdahl B; Tu ST; Matsumoto T; Chan DC; Chung YS; Chen FP; Lewiecki EM; Tsai KS; Yang RS; Ang SB; Huang KE; Chang YF; Chen CH; Lee JK; Ma HI; Xia W; Mithal A; Kendler DL; Cooper C; Hwang JS; Wu CH
J Formos Med Assoc; 2023; 122 Suppl 1():S14-S20. PubMed ID: 36775679
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in Romanian postmenopausal women with osteoporosis and fragility fractures.
Ciubean AD; Ungur RA; Irsay L; Ciortea VM; Borda IM; Onac I; Vesa SC; Buzoianu AD
Clin Interv Aging; 2018; 13():2465-2472. PubMed ID: 30584286
[TBL] [Abstract][Full Text] [Related]
4. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
5. Impact of osteoporosis and bone fracture on health-related quality of life in postmenopausal women.
Palacios S; Neyro JL; Fernández de Cabo S; Chaves J; Rejas J
Climacteric; 2014 Feb; 17(1):60-70. PubMed ID: 23710562
[TBL] [Abstract][Full Text] [Related]
6. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Hsieh SC; Zheng C; Peterson J; Tugwell P; Liu W
Cochrane Database Syst Rev; 2022 May; 5(5):CD004523. PubMed ID: 35502787
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.
Blotman F; Cortet B; Hilliquin P; Avouac B; Allaert FA; Pouchain D; Gaudin AF; Cotté FE; El Hasnaoui A
Drugs Aging; 2007; 24(7):603-14. PubMed ID: 17658910
[TBL] [Abstract][Full Text] [Related]
8. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study.
Eisman J; Clapham S; Kehoe L;
J Bone Miner Res; 2004 Dec; 19(12):1969-75. PubMed ID: 15537439
[TBL] [Abstract][Full Text] [Related]
10. Predictors of osteoporotic fracture in postmenopausal women: a meta-analysis.
Long G; Liu C; Liang T; Zhang Z; Qin Z; Zhan X
J Orthop Surg Res; 2023 Aug; 18(1):574. PubMed ID: 37543616
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in postmenopausal women with osteoporosis: a systematic review and meta-analysis.
Gao S; Zhao Y
Qual Life Res; 2023 Jun; 32(6):1551-1565. PubMed ID: 36383282
[TBL] [Abstract][Full Text] [Related]
12. Setting the new FRAX reference threshold without bone mineral density in Chinese postmenopausal women.
Liu S; Chen R; Ding N; Wang Q; Huang M; Liu H; Xie Z; Ou Y; Sheng Z
J Endocrinol Invest; 2021 Feb; 44(2):347-352. PubMed ID: 32495298
[TBL] [Abstract][Full Text] [Related]
13. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
14. Assessment and hormonal management of osteoporosis.
Trémollieres F
Climacteric; 2019 Apr; 22(2):122-126. PubMed ID: 30624083
[TBL] [Abstract][Full Text] [Related]
15. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
16. Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women.
Chao AS; Chen FP; Lin YC; Huang TS; Fan CM; Yu YW
Taiwan J Obstet Gynecol; 2015 Dec; 54(6):722-5. PubMed ID: 26700992
[TBL] [Abstract][Full Text] [Related]
17. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.
; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Pignone M; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2018 Jun; 319(24):2521-2531. PubMed ID: 29946735
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
19. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
J Intern Med; 2019 Aug; 286(2):221-229. PubMed ID: 30887607
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
